Latest Period
Q4 2025
Security Snapshot
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) Institutional Ownership
CUSIP: 69353Y103
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
62
Shares (Excl. Options)
37,422,687
Price
$1.25
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common stock, par value $0.00001 per share
- Symbol
- PMVP on Nasdaq
- Shares outstanding
- 53,320,277
- Price per share
- $1.25
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 37,422,687
- Total reported value
- $46,777,977
- % of total 13F portfolios
- 0%
- Share change
- -94,369
- Value change
- -$174,801
- Number of holders
- 62
- Price from insider filings
- $1.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share is tracked under CUSIP 69353Y103.
- 62 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 62 to 3 between Q4 2025 and Q1 2026.
- Reported value moved from $46,777,977 to $552,334.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 62 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 69353Y103?
CUSIP 69353Y103 identifies PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 69353Y103:
Significant Owners of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 9.9% | +60% | $6,615,000 | +$2,527,616 | 5,292,000 | +62% | BML Investment Partners, L.P. | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC | 8.9% | $6,702,907 | 4,720,357 | TANG CAPITAL MANAGEMENT, LLC | 16 Sep 2025 | |||
| ArrowMark Colorado Holdings LLC | 5.8% | $3,862,616 | 3,090,093 | ArrowMark Colorado Holdings, LLC | 31 Dec 2025 | |||
| Sio Capital Management, LLC | 5.8% | +16% | $3,845,725 | +$550,040 | 3,076,580 | +17% | Sio Capital Management, LLC | 31 Mar 2026 |
As of 31 Dec 2025, 62 institutional investors reported holding 37,422,687 shares of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP). This represents 70% of the company’s total 53,320,277 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 9.9% | 5,292,000 | 0% | 5.9% | $6,615,000 |
| ORBIMED ADVISORS LLC | 9.3% | 4,975,291 | -17% | 0.13% | $6,219,114 |
| TANG CAPITAL MANAGEMENT LLC | 9.3% | 4,940,000 | +3.2% | 0.31% | $6,175,000 |
| ArrowMark Colorado Holdings LLC | 5.8% | 3,090,093 | -6.4% | 0.08% | $3,862,616 |
| Sio Capital Management, LLC | 4.9% | 2,636,548 | 0% | 0.55% | $3,295,685 |
| Euclidean Capital LLC | 4.9% | 2,627,643 | 0% | 0.89% | $3,284,554 |
| VANGUARD GROUP INC | 4.1% | 2,170,310 | +0.34% | 0% | $2,712,888 |
| ACADIAN ASSET MANAGEMENT LLC | 3.8% | 2,015,770 | -2.4% | 0% | $2,518,000 |
| Stonepine Capital Management, LLC | 2.2% | 1,150,759 | -16% | 1.1% | $1,438,449 |
| BlackRock, Inc. | 2.1% | 1,094,883 | -0.84% | 0% | $1,368,605 |
| TWO SIGMA ADVISERS, LP | 1.6% | 874,100 | +109% | 0% | $1,092,625 |
| TWO SIGMA INVESTMENTS, LP | 1.3% | 706,061 | +162% | 0% | $882,576 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.98% | 524,350 | +664% | 0% | $655,438 |
| JANE STREET GROUP, LLC | 0.94% | 498,641 | +31% | 0% | $623,301 |
| Aldebaran Capital, LLC | 0.9% | 477,988 | -5.2% | 0.54% | $597,485 |
| MARSHALL WACE, LLP | 0.87% | 465,086 | -24% | 0% | $581,358 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.84% | 446,140 | +3.3% | 0% | $557,802 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.8% | 428,853 | +34% | 0.01% | $536,066 |
| NORTHERN TRUST CORP | 0.72% | 382,088 | +0.33% | 0% | $477,611 |
| Walleye Capital LLC | 0.63% | 335,694 | +21% | 0% | $419,618 |
| BANK OF AMERICA CORP /DE/ | 0.45% | 240,138 | +48% | 0% | $300,173 |
| STATE STREET CORP | 0.34% | 183,178 | +16% | 0% | $228,973 |
| RBF Capital, LLC | 0.3% | 162,200 | -34% | 0.01% | $202,750 |
| Assenagon Asset Management S.A. | 0.26% | 140,468 | +14% | 0% | $175,585 |
| EVOKE WEALTH, LLC | 0.25% | 133,122 | 0% | 0% | $166,403 |
Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 441,677 | $552,334 | +$333,800 | $1.24 | 3 |
| 2025 Q4 | 37,422,687 | $46,777,977 | -$174,801 | $1.25 | 62 |
| 2025 Q3 | 37,492,718 | $52,488,395 | +$4,772,987 | $1.40 | 63 |
| 2025 Q2 | 34,680,709 | $36,758,763 | -$2,911,770 | $1.06 | 52 |
| 2025 Q1 | 37,320,031 | $40,676,123 | -$2,281,115 | $1.09 | 54 |
| 2024 Q4 | 38,959,310 | $58,833,270 | -$767,790 | $1.51 | 70 |
| 2024 Q3 | 39,023,873 | $58,153,846 | -$2,416,795 | $1.49 | 73 |
| 2024 Q2 | 40,492,185 | $65,594,864 | -$3,771,661 | $1.62 | 91 |
| 2024 Q1 | 42,725,320 | $72,627,924 | -$11,853,919 | $1.70 | 96 |
| 2023 Q4 | 46,465,983 | $144,025,863 | -$52,160,467 | $3.10 | 97 |
| 2023 Q3 | 54,236,025 | $333,006,052 | +$15,386,619 | $6.14 | 103 |
| 2023 Q2 | 51,696,984 | $323,689,509 | +$3,281,155 | $6.26 | 104 |
| 2023 Q1 | 51,513,177 | $245,718,220 | -$16,150,590 | $4.77 | 111 |
| 2022 Q4 | 54,555,170 | $474,625,571 | -$38,255,414 | $8.70 | 113 |
| 2022 Q3 | 58,187,852 | $692,436,457 | -$36,596,424 | $11.90 | 116 |
| 2022 Q2 | 61,123,657 | $870,921,498 | +$53,476,878 | $14.25 | 105 |
| 2022 Q1 | 55,249,345 | $1,150,065,944 | +$162,099,243 | $20.82 | 98 |
| 2021 Q4 | 47,470,437 | $1,096,597,184 | +$15,190,740 | $23.10 | 102 |
| 2021 Q3 | 43,990,444 | $1,310,907,931 | +$46,789,977 | $29.80 | 91 |
| 2021 Q2 | 42,241,228 | $1,442,956,792 | +$80,038,413 | $34.16 | 83 |
| 2021 Q1 | 39,915,363 | $1,312,819,295 | +$51,865,975 | $32.89 | 81 |
| 2020 Q4 | 38,212,089 | $2,335,342,669 | +$185,049,476 | $61.51 | 72 |
| 2020 Q3 | 31,212,908 | $1,098,804,001 | +$1,098,804,001 | $35.50 | 51 |